To cite this article: Puetz J. Nano-evidence for joint microbleeds in hemophilia patients. J Thromb Haemost 2018; 16: 1914-7. Summary. The concept of joint microbleeding in hemophilia patients was first proposed over 10 years ago. This was based on unexpected abnormalities found in medical imaging studies of asymptomatic joints. Since then, there have been no published studies confirming the presence of joint microbleeds. This critique will review the evidence for and against joint microbleeding in hemophilia patients and the potential implications.
Introduction
The Joint Outcome Study was a randomized controlled study in boys with severe hemophilia and demonstrated improved outcomes for boys receiving prophylaxis [1] . One surprising result of the study was magnetic resonance imaging (MRI) abnormalities in the joints of boys who did not have clinically evident joint bleeds. The authors proposed 'that chronic microhemorrhage into the joints or subchondral bone in young boys with hemophilia causes deterioration of joints without clinical evidence of hemarthrosis' [1] . In the last decade there have not been any publications in the medical literature confirming the existence of joint microbleeding, nor has it been formally defined [2] . Joint microbleeding occurs when there is asymptomatic (subclinical) leakage of microscopic amounts of blood into a joint. Despite this, joint microbleeding has been promoted as a clinically relevant medical entity to physicians and consumers [3] [4] [5] . This review will evaluate the evidence for and against joint microbleeding in hemophilia patients.
MIFFS in hemophilia patients
The Joint Outcome Study was not the first or only study of joints in hemophilia patients to demonstrate medical imaging findings in joints free of clinically evident bleeds and symptoms (MIFFS). At least 10 studies have evaluated MIFFS [1, [6] [7] [8] [9] [10] [11] [12] [13] [14] . Most of the investigators interpreted the MIFFS as pathological and suggested they were related to bleeding [1, [6] [7] [8] [9] [10] 13, 14] . However, only the Canadian Tailored Prophylaxis Study demonstrated the presence of blood (hemosiderin) in asymptomatic joints [8] . In the remainder of the studies, either there was no hemosiderin present or it was not reported [1, 6, 7, [9] [10] [11] [12] [13] [14] . The imaging modality used for the Canadian study was a T2 gradient echo image, an imaging technique that is known to overestimate hemosiderin in joints [15] . Despite the limited indirect evidence for joint microbleeding, it would be reasonable to assume the MIFFS in hemophilia subjects were related to bleeding if MIFFS were unique to hemophilia. They are not.
MIFFS in healthy controls
Numerous controlled studies of joints in healthy, asymptomatic people have demonstrated the presence of MIFFS [16] [17] [18] [19] [20] [21] . They occur quite commonly. For instance, disk degeneration can be found in up to 37% of healthy, asymptomatic 20-year-old subjects and the prevalence rises to 96% of people in their 80s [20] .
Many MIFFS resemble what one would expect to see in hemophilia patients, such as synovitis, cartilage erosion and subchondral cysts [16] [17] [18] [19] 21] . This begs the question, are the MIFFS seen in hemophilia joints due to bleeding, or are they a part of the natural aging process? The best way to answer this question is through controlled studies.
Controlled studies
Unfortunately, there are few studies comparing MIFFS in patients with hemophilia to those in healthy controls. One group of investigators was concerned that joint effusions could falsely elevate the MRI score [22] . They found that knee effusions are more common in healthy controls than hemophilia subjects. Another group used infrared thermographic imaging to evaluate the joints of hemophilia patients without clinically evident joint bleeds and agematched healthy controls [14] . Overall, the hemophilia subjects had higher scores, suggesting more joint disease. However, analysis of individual joints showed the percentage of abnormal joints was higher in the healthy subjects' elbows, higher in the hemophilia subjects' ankles, and the same in knees. A third study compared MRI to ultrasound imaging studies in hemophilia subjects in their 20s and age-matched controls [10] . The included joints had no clinically evident bleeds or symptoms. There was excellent correlation between MRI and ultrasound findings. Subjects with hemophilia had higher joint MRI and ultrasound scores than healthy controls.
Overall, there is one study showing a higher rate of MIFFS in healthy controls, one with mixed results, and one showing a higher rate of MIFFS in hemophilia subjects. These studies were hampered by small sample size and reliance on patient recall to determine the absence of a joint bleed. Clearly, additional studies are required to determine if MIFFS in hemophilia patients are due to bleeding or are part of the natural aging process.
Cerebral microbleeding
Although there is no direct evidence for joint microbleeding in hemophilia patients, there is strong evidence for cerebral microbleeding [23, 24] . Small regions of hemosiderin have been identified in brain MRI imaging for decades [25] . Histopathological specimens of brain sections correlating with regions of hemosiderin deposition on MRI imaging have confirmed the presence of microbleeding in people without hemophilia [26] . Cerebral microbleeding has been found in people with dementia and cerebrovascular disease and healthy controls [25] . It is generally thought to be due to small vessel disease [25, 26] . Recently, imaging studies have confirmed the presence of cerebral microbleeding in patients with hemophilia [23, 24] . One study found that the prevalence of cerebral microbleeding in hemophilia subjects is the same as controls [23] . This suggests that cerebral microbleeding in hemophilia patients is also due to small vessel disease, and not due to their underlying bleeding disorder. Why should this be? If a small cerebral vessel ruptures, one might expect a large amount of bleeding due to the hemophilia patient's factor deficiency: microbleeding turns into macrobleeding. However, tissue factor is expressed in large amounts in the brain parenchyma [27, 28] . Conceivably, the tissue factor pathway is robust enough in the brain of hemophilia patients to prevent microbleeding from turning into macrobleeding (Fig. 1) . If this proposed mechanism is true, then we should expect the last place to find microbleeding in a hemophilia patient is in the synovium. Tissue factor expression is sparse in the synovium of joints [28] . Hence the tissue factor pathway is not robust and microbleeding would not be expected to occur in the joints of hemophilia patients.
Another possible mechanism to explain microbleeding in hemophilia patients' joints would be low level factor (F) VIII activity. Perhaps low level FVIII activity would be sufficient to prevent microbleeding from turning into macrobleeding, but not high enough to prevent microbleeding? This could be seen in patients with severe hemophilia on prophylaxis as they approach their trough FVIII activity level. However, it might also be expected to be seen with mild hemophilia. Chronic joint disease and microbleeding are not hallmarks of mild hemophilia.
Subclinical bleeding vs. microbleeding
In their ultrasound study of hemophilia joints, de la Corte-Rodriguez et al. seem to equate subclinical joint bleeding with joint microbleeding [13] . Although joint microbleeding (if it is ever shown to exist) would be one form of subclinical bleeding, several other scenarios for subclinical bleeding are possible. One could easily imagine a toddler with hemophilia who is on prophylaxis who develops a joint (macro) bleed. Perhaps his parents do not recognize the bleed, but infuse as part of routine prophylaxis. The joint bleed could resolve following the infusion, and the bleed would never be clinically evident. Or imagine a school-age child who participates in an activity forbidden by his parents. If the child suffers a bleed because of the activity, he might keep the bleed hidden from his parents, and the bleed would not be clinically evident. Perhaps a young adult volunteers for an imaging study of joints without clinically evident bleeds. He may not recall a bleed that happened several years ago and be inappropriately enrolled in the study. These scenarios, and there are others, would result in subclinical joint bleeding, but not necessarily joint microbleeding. Subclinical bleeding and microbleeding should not be used interchangeably, because they are not necessarily the same.
Proving joint microbleeds
Although there is currently no evidence for joint microbleeding in hemophilia patients, this does not mean it does not exist. Several lines of evidence would be necessary to demonstrate the existence of joint microbleeding, including: (i) showing that MIFFS are more prevalent in hemophilia subjects compared with the general population; (ii) demonstrating that MIFFS are due to bleeding (it is possible that MIFFS are related to a factor deficiency but not necessarily bleeding); and (iii) demonstrating that the MIFFS are due to microbleeding. Sorting out microbleeding from other types of subclinical bleeding will be challenging. This is especially true if a single missed joint (macro) bleed could cause permanent joint damage. In a mouse model of joint bleeding, a single joint (macro) hemorrhage has been shown to cause permanent joint damage [29] . It is uncertain if this is also the case in humans.
Joint microbleed? So what?
If joint microbleeding were proven to occur, what then? There still is no evidence that MIFFS are clinically relevant. One canine model of joint microbleeding did show mild synovial inflammation following injection of small amounts of autologous blood into a joint, but the dogs did not develop chronic joint changes [30] . There are no natural history studies of MIFFS in people with hemophilia. It is possible that hemophilia patients with MIFFS will go on to develop joint disease. That is an assumption that is yet to be proven, and for this reason natural history studies should be carried out. Until it is shown that MIFFS progress to joint disease there is no reason to target prophylaxis to a higher trough level.
Conclusions
MIFFS in hemophilia patients are a significant clinical issue and deserve appropriate investigation. Assuming that MIFFS in hemophilia patients are due to microbleeding when they are not (or vice versa) can lead to ineffective medical interventions. Until such time that there is strong evidence that MIFFS are due to microbleeding, Hemostasis is initiated through the tissue factor pathway but cannot be amplified through the intrinsic pathway. There is not a sufficient amount of tissue factor present to generate a burst of thrombin. Joint macrobleeding occurs. F, fibrin; IIa, thrombin; IXa, activated factor IX; TF, tissue factor; Va, activated factor V; VIIa, activated factor VII; VIIIa, activated factor VIII; Xa, activated factor X; Xia -activated factor XI.
and microbleeding is clinically relevant, joint microbleeding should not be promoted as a significant entity.
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